^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMP9064

    i
    Other names: IMP9064, IMP-9064, IMP 9064
    Associations

    News

    Trials
    Company:
    IMPACT Therap
    Drug class:
    ATR inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=61, Recruiting, Impact Therapeutics, Inc. | Phase classification: P1/2 --> P1
    Phase classification • Combination therapy • Metastases
    |
    senaparib (IMP4297) • IMP9064
    3years
    Burning Rock Collaborates with IMPACT Therapeutics to Provide Testing Services in Developing IMP9064 in both US and China (GlobeNewswire)
    "Burning Rock Biotech Limited...today announced a collaboration with IMPACT Therapeutics where Burning Rock provides testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, which has received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, and will begin soon in the U.S. The collaboration will be supported by Burning Rock’s Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited labs in Guangzhou, China and California, U.S."
    Licensing / partnership • IND • New P1/2 trial
    |
    IMP9064